semaglutide gastric stasis class action in michigan glp-1 diarrhea lawsuit glp-1 in michigan GLP-1 Agonist Delayed Gastric Emptying: Clinical Implications Integrated Insights into Metabolic and

Description

During the 24-week observation, liraglutide did not improve LVEF but rather caused more death, ventricular arrhythmia, and atrial fibrillation, compared with the placebo

Many patients taking semaglutide wonder whether adding magnesium supplements could enhance their results or improve side effect management

Differential effects of a glucagon-like peptide 1 receptor agonist in non-alcoholic fatty liver disease and in response to hepatectomy

these changes are thought to be related to changes in cravings, hunger and fullness (Mozafarriun et al 2025)

Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended References Wegovy [package insert]